Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin CH0012032048
Ticker ROG.VX
Company ROCHE
Currency CHF
Price
Aware Investor Index (AII) 31.2097
Recommendation STRONG BUY
P/E 23.50
ROE 31.75 %
Capitalization 223,437,468,170 $
Dividend Yield 3.30 %
P/S 4.06
AII Position 59
P/E Position 323
ROE Position 78
Capitalization Position 27
Dividend Yield Position 199
Sales 53,299,000,000 CHF
10-Year Average Earnings 9,210,600,000 CHF
Shares Outstanding 860,000,000
Equity 29,007,000,000 CHF
Dividend per Share 8.3 CHF
Industry Pharmaceutical
Country Switzerland
ROCHE Investor Relations Web Site http://www.roche.com/investors.htm







Sales:

YEAR MONTH AMOUNT
2017 12 53,299,000,000.00 CHF
2016 12 50,576,000,000.00 CHF
2015 12 48,145,000,000.00 CHF
2014 12 47,462,000,000.00 CHF
2013 12 46,780,000,000.00 CHF

Earnings:

YEAR MONTH AMOUNT
2017 12 8,825,000,000.00 CHF
2016 12 9,733,000,000.00 CHF
2015 12 8,863,000,000.00 CHF
2014 12 9,332,000,000.00 CHF
2013 12 11,164,000,000.00 CHF
2012 12 9,427,000,000.00 CHF
2011 12 9,343,000,000.00 CHF
2010 12 8,666,000,000.00 CHF
2009 12 7,784,000,000.00 CHF
2008 12 8,969,000,000.00 CHF

Equity:

YEAR MONTH AMOUNT
2017 12 29,007,000,000.00 CHF
2016 12 26,402,000,000.00 CHF
2015 12 23,300,000,000.00 CHF
2014 12 21,558,000,000.00 CHF
2013 12 21,241,000,000.00 CHF
2012 12 16,728,000,000.00 CHF
2011 12 14,482,000,000.00 CHF

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 860,000,000
2016 12 860,000,000
2015 12 862,000,000
2014 12 863,000,000
2013 12 863,000,000
2012 12 848,000,000
2011 12 849,000,000

 












Bloomberg News for ROCHE:



Google News for ROCHE:

CNBC - 26 Jul 2018
Roche raises outlook for 2018 as new drugs gain traction
Swiss drugmaker Roche lifted its 2018 outlook on Thursday for the second time this year, after first-half sales and profit easily beat analyst ...
Business Insider - 15 Feb 2018
Pharma giant Roche is buying cancer tech startup Flatiron Health for ...
Pharma giant Roche is acquiring Flatiron Health for $1.9 billion. The New York-based cancer technology startup had previously been valued at ...
Forbes - 11 Dec 2017
Roche's Fight With Pfizer May Be Just The Beginning
Roche recently sued Pfizer to block the latter's biosimilar (generic version) for Herceptin- a cancer biologic that earned $2.5 billion in sales in ...
Reuters - 28 Jan 2016
Roche annual profit disappoints, outlook muted
BASEL, Switzerland (Reuters) - Cancer drug maker Roche ROG.VX followed Swiss rival Novartis NOVN.VX in disappointing shareholders with ...
Seeking Alpha - 25 Oct 2017
Roche: Buying The Dip
Roche Holding is a mega cap multinational biotech and lab diagnostics company that has seen its stock perform badly lately. Since I look at the ...
Reuters - 2 Feb 2016
Roche eyes acquisition of Pacific Biosciences: sources
(Reuters) - Roche Holding AG ROG.VX has in recent weeks approached Pacific Biosciences of California Inc (PACB.O) to discuss acquiring the ...
Investopedia - 22 Dec 2015
The Top 10 Biotechnology Companies (JNJ, ROG.VX)
Founded in Switzerland in 1896, Roche (NASDAQ: ROG.VX) calls itself the largest biotech company in the world, with 17 biopharmaceuticals ...
MarketWatch - 12 Aug 2015
Roche buys privately-held GeneWEAVE BioSciences
ZURICH - Roche Holding AG (ROG.VX) Thursday said it has agreed to buy a U.S. microbiology diagnostic company in a deal which could rise ...
Reuters UK - 1 Jul 2014
Roche to buy US biotech firm Seragon for up to $1.7 billion
ZURICH (Reuters) - Roche Holding AG ROG.VX said it would pay up to $1.725 billion to buy Seragon Pharmaceuticals, a privately-held U.S. ...
Reuters - 20 Oct 2014
NewLink in $1 billion deal with Roche to develop cancer drug
(Reuters) - NewLink Genetics Corp (NLNK.O) said it entered into an agreement with Roche Holding AG ROG.VX to develop NewLink's cancer ...


Back